A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

NCT05782764 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lung Squamous Cell Carcinoma

Interventions

DRUG: To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).

Sponsor

Xuzhou Medical University